Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human Trop-2 Monoclonal Antibody

Catalog No.: YR0018

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SEC-HPLC

Background

Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Sacituzumab Biosimilar

Isotype
Human IgG1 kappa

Immunogen
Human Trop-2

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer
1×PBS pH 7.3

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn


Product Information

Production
Purified from cell culture supernatant in an animal-free facility


Purification
Protein A or G purification

Storage
Store at -20℃

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human Trop-2 (Research Grade Sacituzumab Biosimilar) Monoclonal Antibody to Trop-2. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human Trop-2 SPR assay. Determined through SPR assay, the Human Anti-Human Trop-2 (Research Grade Sacituzumab Biosimilar) Monoclonal Antibody is Capable of binding to Human Trop-2 with an affinity constant of 18.8 nM.